Antibody-Mediated Delivery of Chimeric BRD4 Degraders. Part 2: Improvement of In Vitro Antiproliferation Activity and In Vivo Antitumor Efficacy

Peter S. Dragovich(Pfizer (United States)), Xiaoyu Zhu(WuXi AppTec (China)), Leanna R. Staben, Shang‐Fan Yu(Genesys (United States)), Tracy Kleinheinz(Genesys (United States)), Jack Sadowsky(Genesys (United States)), Jeremy Murray(Novartis (Switzerland)), Josefa dela Cruz-Chuh, Rebecca K. Rowntree(Genesys (United States)), Donglu Zhang(Acentech (United States)), Pragya Adhikari(Genesys (United States)), Katherine R. Kozak(University of California, Los Angeles), Aaron Fullerton, Emel Adaligil, BinQing Wei, Zijin Xu(WuXi AppTec (China)), Thomas H. Pillow(Genesys (United States)), Aimee O’Donohue(Genesys (United States)), William S. Sawyer, Nicholas Corr, Steven J. Hartman(Washington University in St. Louis), Jian Wang(The University of Texas MD Anderson Cancer Center), Hongyan Zhang(Tianjin University), Jinhua Chen(WuXi AppTec (China)), Liling Liu, Hui Yao(Jinan University), Hao Zhou(Institute of Chemical Industry of Forest Products), Fan Jiang(Peking University), Wentao Wei(Viva Biotech (China)), Susan Kaufman(Genesys (United States)), Yongxin Zhao(Nanjing Normal University), Robert A. Blake(Exelixis (United States)), John Wai(WuXi AppTec (China)), Geoffrey Del Rosario(Genesys (United States)), Shenhua Zhang(Viva Biotech (China)), Ying Lu(WuXi AppTec (China)), Melinda M. Mulvihill(Genesys (United States))
Journal of Medicinal Chemistry
February 17, 2021
Cited by 168


Related Papers